Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.
You may also be interested in...
Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow
Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.
Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow
Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.
Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”
Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.